Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shang Yi

Showing results (311-320 of 357) with videos related to

Pageof 36
Sort By:
Blood|November 8, 2008
Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survivalTiffany Ting-Fang Shih, Hsin-An Hou, Chieh-Yu Liu, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2024
Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomesRou-Zhen Chen, Po-Liang Lu, Tsung-Ying Yang, et al.
BMC Cancer|June 26, 2019
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndromeHuai-Hsuan Huang, Fei-Yun Chen, Wen-Chien Chou, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
American Journal of Hematology|April 12, 2014
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network studyKihyun Kim, Jae Hoon Lee, Jin Seok Kim, et al.
Frontiers in Neuroscience|May 9, 2022
Control of Behavioral Arousal and Defense by a Glutamatergic Midbrain-Amygdala Pathway in MiceShang-Yi Chen, Jing Yao, Yu-Duan Hu, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Bioengineering & Translational Medicine|October 17, 2022
Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibodyChih-Yen Lin, Wen-Hung Wang, Meng-Chi Li, et al.
Blood Cancer Journal|October 10, 2019
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma NetworkCinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, et al.
Pageof 36

Showing results (311-320 of 357) with videos related to

Sort By:
Pageof 36
Blood|November 8, 2008
Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survivalTiffany Ting-Fang Shih, Hsin-An Hou, Chieh-Yu Liu, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2024
Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomesRou-Zhen Chen, Po-Liang Lu, Tsung-Ying Yang, et al.
BMC Cancer|June 26, 2019
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndromeHuai-Hsuan Huang, Fei-Yun Chen, Wen-Chien Chou, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
American Journal of Hematology|April 12, 2014
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network studyKihyun Kim, Jae Hoon Lee, Jin Seok Kim, et al.
Frontiers in Neuroscience|May 9, 2022
Control of Behavioral Arousal and Defense by a Glutamatergic Midbrain-Amygdala Pathway in MiceShang-Yi Chen, Jing Yao, Yu-Duan Hu, et al.
Annals of Hematology|June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myelomaIvan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Bioengineering & Translational Medicine|October 17, 2022
Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibodyChih-Yen Lin, Wen-Hung Wang, Meng-Chi Li, et al.
Blood Cancer Journal|October 10, 2019
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma NetworkCinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, et al.
Pageof 36